Turning Point Brands, Inc. (TPB) is a consumer products company best known for Zig-Zag rolling papers and cigar wraps, Stoker's moist snuff, and a fast-growing portfolio of nicotine pouches. After a powerful rally that carried the stock to a 52-week high of $146.90 in late February 2026, shares have pulled back sharply and recently closed around $75.22.
That retreat has reignited a familiar investor question: can TPB reclaim the psychologically important $100 level? The figure is appealing because it is a round number, because the stock has already traded comfortably above it, and because it sits below the Street's consensus price target — making it a realistic checkpoint rather than a moonshot.
TPB's sharp decline from its February peak reflects a meaningful de-rating. The stock's trailing price-to-earnings (P/E) ratio now sits around 33 times earnings, while its 52-week range spans $65.80 to $146.90. In other words, even after the correction, the shares have not fallen to their low point of the year, but they are closer to that floor than to their former high.
That positioning matters for the $100 question. A return to triple digits would require a gain of roughly 33% from current levels — substantial, but far less dramatic than the move already delivered during the stock's earlier surge.
The most important catalyst is the company's pivot toward modern oral nicotine. TPB's FRE brand and the newer ALP line have become the primary growth engine, and management has repeatedly raised full-year guidance as pouch sales accelerate. In late 2025, the company lifted its Modern Oral revenue outlook and delivered quarterly results that exceeded Wall Street's revenue and EBITDA (earnings before interest, taxes, depreciation, and amortization) expectations.
That momentum has translated directly into a stream of analyst upgrades. Oppenheimer has maintained an Outperform rating while raising its target from $110 to $120, and Alliance Global Partners lifted its Buy-rated target from $103 to $110. More recently, Needham upgraded the shares with a $125 target. The consensus 12-month price target across covering analysts now sits near $125, with a high estimate around $140 — comfortably above the $100 level in question.
Several obstacles stand between TPB and $100. First, the stock's valuation is not obviously cheap after its run, and the sharp correction suggests some investors view the earlier multiple as unsustainable. Second, the nicotine pouch category is highly competitive, with deep-pocketed rivals aggressively expanding their own oral-nicotine offerings, which could pressure TPB's market share and pricing over time.
Regulatory risk is the third and perhaps most persistent concern. The U.S. Food and Drug Administration (FDA) retains significant authority over nicotine products, and any adverse action on pouch marketing or authorizations could disrupt growth assumptions. Each of these factors could slow the momentum needed to reclaim triple-digit territory.
From a technical analysis perspective, the 52-week low near $65.80 represents the clearest downside support level, while the round-number $100 mark acts as both a psychological target and a potential resistance level once approached. Between them, the stock's recent trading range has provided no firm intermediate floor, meaning a sustained move toward $100 would likely require buyers to defend progressively higher levels rather than relying on a single catalyst.
The analyst community is broadly constructive. With an average rating described as a Strong Buy and a consensus target near $125, the prevailing view already assumes TPB will trade above $100 within the next twelve months. That does not guarantee the outcome, but it does mean the $100 objective is consistent with — and in fact below — mainstream analyst expectations, rather than a contrarian or aggressive forecast.
For traders who want a more systematic way to track stocks like Turning Point Brands, Tickeron's AI Daily Buy/Sell Signals offer an artificial intelligence-driven approach to market monitoring. The tool continuously scans thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to uncover new opportunities, monitor existing positions, and identify shifting market trends more efficiently than manual review alone. For those following TPB's journey back toward $100, such signals can provide an additional layer of context for timing and trend assessment.
Can TPB reach $100? The evidence suggests the target is realistic over a twelve-month horizon, primarily because the company's nicotine-pouch growth remains intact and Wall Street's consensus already anticipates a move above that level. The strongest supporting factors are accelerating Modern Oral sales, repeated guidance increases, and a steady series of analyst price-target raises.
The primary risks are equally clear: a still-demanding valuation, fierce competition in oral nicotine, and FDA regulatory uncertainty. Investors monitoring TPB should watch pouch-sales trends, quarterly EBITDA, any changes to analyst targets, and regulatory developments — all of which will determine whether the climb back to triple digits happens sooner, later, or not at all.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TPB has been loosely correlated with PM. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if TPB jumps, then PM could also see price increases.